Use of Acute Headache and Migraine Medications in Patients with Episodic Migraine in the STRIVE Phase 3 Trial of Erenumab for Migraine Prevention (P4.118)

Toanalyze (A) change in acute headache medication days/month (AHM, includingacute migraine-specific medications (AMSM) as well as paracetamol, NSAIDS etc.)in the overall population as 97.7% used AHM during baseline; (B) change in AMSM days/month in the subgroup who used AMSM during baseline.